235 related articles for article (PubMed ID: 25959631)
1. Pharmacokinetics of tenofovir during pregnancy and postpartum.
Best BM; Burchett S; Li H; Stek A; Hu C; Wang J; Hawkins E; Byroads M; Watts DH; Smith E; Fletcher CV; Capparelli EV; Mirochnick M;
HIV Med; 2015 Sep; 16(8):502-11. PubMed ID: 25959631
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
[TBL] [Abstract][Full Text] [Related]
3. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
Cressey TR; Stek A; Capparelli E; Bowonwatanuwong C; Prommas S; Sirivatanapa P; Yuthavisuthi P; Neungton C; Huo Y; Smith E; Best BM; Mirochnick M;
J Acquir Immune Defic Syndr; 2012 Mar; 59(3):245-52. PubMed ID: 22083071
[TBL] [Abstract][Full Text] [Related]
5. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
[TBL] [Abstract][Full Text] [Related]
6. Effect of pregnancy on emtricitabine pharmacokinetics.
Stek AM; Best BM; Luo W; Capparelli E; Burchett S; Hu C; Li H; Read JS; Jennings A; Barr E; Smith E; Rossi SS; Mirochnick M
HIV Med; 2012 Apr; 13(4):226-35. PubMed ID: 22129166
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
Tran AH; Best BM; Stek A; Wang J; Capparelli EV; Burchett SK; Kreitchmann R; Rungruengthanakit K; George K; Cressey TR; Chakhtoura N; Smith E; Shapiro DE; Mirochnick M;
J Acquir Immune Defic Syndr; 2016 Jul; 72(3):289-96. PubMed ID: 26918544
[TBL] [Abstract][Full Text] [Related]
8. Reduced indinavir exposure during pregnancy.
Cressey TR; Best BM; Achalapong J; Stek A; Wang J; Chotivanich N; Yuthavisuthi P; Suriyachai P; Prommas S; Shapiro DE; Watts DH; Smith E; Capparelli E; Kreitchmann R; Mirochnick M;
Br J Clin Pharmacol; 2013 Sep; 76(3):475-83. PubMed ID: 23305215
[TBL] [Abstract][Full Text] [Related]
9. Reduced lopinavir exposure during pregnancy.
Stek AM; Mirochnick M; Capparelli E; Best BM; Hu C; Burchett SK; Elgie C; Holland DT; Smith E; Tuomala R; Cotter A; Read JS
AIDS; 2006 Oct; 20(15):1931-9. PubMed ID: 16988514
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.
Stek A; Best BM; Wang J; Capparelli EV; Burchett SK; Kreitchmann R; Rungruengthanakit K; Cressey TR; Mofenson LM; Smith E; Shapiro D; Mirochnick M
J Acquir Immune Defic Syndr; 2015 Sep; 70(1):33-41. PubMed ID: 25950206
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.
Read JS; Best BM; Stek AM; Hu C; Capparelli EV; Holland DT; Burchett SK; Smith ME; Sheeran EC; Shearer WT; Febo I; Mirochnick M
HIV Med; 2008 Nov; 9(10):875-82. PubMed ID: 18795962
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women.
Colbers AP; Hawkins DA; Gingelmaier A; Kabeya K; Rockstroh JK; Wyen C; Weizsäcker K; Sadiq ST; Ivanovic J; Giaquinto C; Taylor GP; Moltó J; Burger DM;
AIDS; 2013 Mar; 27(5):739-48. PubMed ID: 23169329
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate.
Eke AC; Shoji K; Best BM; Momper JD; Stek AM; Cressey TR; Mirochnick M; Capparelli EV
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318014
[TBL] [Abstract][Full Text] [Related]
14. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations.
Else LJ; Douglas M; Dickinson L; Back DJ; Khoo SH; Taylor GP
Antimicrob Agents Chemother; 2012 Feb; 56(2):816-24. PubMed ID: 22106215
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir and tenofovir interaction observed in non-pregnant adults altered during pregnancy.
Mulligan N; Salama E; Momper JD; Capparelli EV; Stek A; Chakhtoura N; Mirochnick M; Best BM;
J Clin Pharm Ther; 2021 Oct; 46(5):1459-1464. PubMed ID: 34254323
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s.
Brooks KM; Pinilla M; Stek AM; Shapiro DE; Barr E; Febo IL; Paul ME; Deville JG; George K; Knowles K; Rungruengthanakit K; Browning R; Chakhtoura N; Capparelli EV; Mirochnick M; Best BM;
J Acquir Immune Defic Syndr; 2022 Jul; 90(3):343-350. PubMed ID: 35195573
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum.
Eke AC; McCormack SA; Best BM; Stek AM; Wang J; Kreitchmann R; Shapiro D; Smith E; Mofenson LM; Capparelli EV; Mirochnick M;
J Clin Pharmacol; 2019 Mar; 59(3):386-393. PubMed ID: 30358179
[TBL] [Abstract][Full Text] [Related]
19. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.
Mirochnick M; Taha T; Kreitchmann R; Nielsen-Saines K; Kumwenda N; Joao E; Pinto J; Santos B; Parsons T; Kearney B; Emel L; Herron C; Richardson P; Hudelson SE; Eshleman SH; George K; Fowler MG; Sato P; Mofenson L;
J Acquir Immune Defic Syndr; 2014 Jan; 65(1):33-41. PubMed ID: 23979002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
